

In the claims

The following amendments are made with respect to the claims in the international application PCT/GB03/02586.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Currently amended). ~~Use of nefopam for the manufacture of a medicament for use in the treatment of~~ A method for treating a condition selected from the group consisting of nausea, dizziness, blurred vision and emesis, wherein said method comprises administering, to a patient in need of such treatment, an effective amount of nefopam.

2 (Currently amended). ~~Use~~The method, according to claim 1, wherein the condition is acute, delayed, postoperative, late-phase or anticipatory emesis.

3 (Currently amended). ~~Use~~The method, according to claim 1 ~~or claim 2~~, wherein the condition is associated with dysmenorrhoea, migraine, cancer or other pain condition.

4 (Currently amended). ~~Use~~The method, according to claim 1 ~~or claim 2~~, wherein the condition is induced by one or more of radiation, toxins, pregnancy, alcohol withdrawal, nicotine withdrawal, drug withdrawal, vestibular disorder, motion, post-operative sickness, surgery, gastrointestinal obstruction, reduced gastrointestinal mobility, visceral pain or increased or decreased intracranial pressure.

5 (Currently amended). ~~Use~~The method, according to ~~any preceding claim 1~~, wherein the condition is drug-induced.

6 (Currently amended). ~~Use~~The method, according to claim 5, wherein the condition is induced by chemotherapy.

7 (Currently amended). ~~Use~~The method, according to claim 5 wherein the condition is induced by an opioid analgesic.

8 (Currently amended). ~~Use~~The method, according to ~~any preceding claim 1~~, wherein the patient is also administered another agent that has anti-emetic properties.

9 (Currently amended). ~~Use~~The method, according to claim 8, wherein said agent is selected from the group consisting of phenothiazines, 5HT3 receptor antagonists, dopamine antagonists, anticholinergic agents, anti-histamines, histamine analogues, cannabinoids, corticosteroids, GABA receptor antagonists, NK1 receptor antagonists, and  $\alpha_2$  and  $\alpha_3$  adrenoceptor antagonists.

10 (Currently amended). ~~Use~~The method, according to claim 8, wherein said agent is selected from the group consisting of cyclizine, dolasetron, granisetron, andansetron, tropisetron, nabilone, scopolenine, cinnerizine, promethazine, betahistine, dexamethasone, methylprednisolone, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, thiethylperazine, droperidol, domperidone and haloperidol.